Astellas gains extensive new territorial rights to Eligard
This article was originally published in Scrip
Astellas' European subsidiary has acquired from the private US firm Tolmar Holdings a licence to commercialise the prostate cancer drug Eligard (leuprolide acetate) in a broad range of Asian, Middle Eastern, North African and CIS countries.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.